MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.4088
-0.0053 (-1.28%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.4141
Open0.4018
Bid0.3600 x 900
Ask0.5250 x 800
Day's Range0.4018 - 0.4150
52 Week Range0.3240 - 1.6000
Volume71,400
Avg. Volume373,337
Market Cap38.663M
Beta2.15
PE Ratio (TTM)N/A
EPS (TTM)-0.1630
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • GlobeNewswire16 days ago

    Matinas BioPharma Announces Appointment of Industry Leader Patrick G. LePore to Board of Directors

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced the appointment of Patrick G. LePore as Vice Chairman to the Company’s Board of Directors. “We are delighted to welcome Pat to the Matinas Board,” commented Herbert Conrad, Chairman of the Matinas BioPharma Board of Directors.

  • GlobeNewswire17 days ago

    Matinas BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

    As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss the Company’s differentiated LNC drug delivery platform which offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including small molecules, nucleic acid polymers, proteins, peptides, vaccines, as well as the targeted delivery of gene editing technologies. Additionally, Mr. Jabbour will provide an overview of the Company's lead and platform-validating product candidate, MAT2203, which utilizes its proprietary LNC formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017 and a positive face-to-face interaction with the FDA in 2018, Matinas has designed a streamlined and risk-mitigated development program focused on  a potential pivotal Phase 2 trial of MAT2203 for the prevention of IFIs in patients with acute lymphoblastic leukemia.

  • GlobeNewswirelast month

    Matinas BioPharma to Present at the U.S. FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, announced today that Raphael Mannino, Ph.D., Chief Scientific Officer of Matinas will present at the public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections,” being held by the U.S. Food and Drug Administration (FDA) August 21-22, 2018. The purpose of the public workshop is to discuss the general development considerations of non-traditional therapies, including preclinical development, early clinical studies, and Phase 3 clinical trial designs to evaluate safety and efficacy.

  • GlobeNewswirelast month

    Matinas BioPharma Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    –Management intently focused on advancing proprietary and highly differentiated lipid nano-crystal platform delivery technology–. –Multiple discussions with strategic partners remain ongoing–. –­Lead platform-validating ...

  • ACCESSWIRE2 months ago

    Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on NEPT sign up now at www.wallstequities.com/registration. Under evaluation this morning are the following equities: Magenta Therapeutics Inc. (MGTA), Matinas BioPharma Holdings Inc. (NYSE AMER: MTNB), MyoKardia Inc. (NASDAQ: MYOK), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).

  • GlobeNewswire2 months ago

    NIH and Matinas BioPharma Announce Research Collaboration to Identify Novel HIV Therapy Utilizing LNC Platform Delivery Technology

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative medicines using its proprietary lipid nano-crystal (LNC) platform delivery technology, and the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), today announced a research collaboration focused on the development of a novel therapy for the treatment of human immunodeficiency virus (HIV) combining targeted antisense oligonucleotides (ASO) and Matinas’ LNC delivery technology.

  • Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): Is Breakeven Near?
    Simply Wall St.4 months ago

    Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): Is Breakeven Near?

    Matinas BioPharma Holdings Inc’s (AMEX:MTNB): Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing antifungal and anti-bacterial therapeutics for the treatment of various infections in theRead More...

  • ACCESSWIRE6 months ago

    Matinas BioPharma Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / Matinas BioPharma Holdings, Inc. (NYSE American: MTNB ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018, at ...